Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Endo Health Turns First Quarter Profit, Affirms 2013 Forecast

By Pharmaceutical Processing | May 7, 2013

Endo Health Solutions Inc. turned a first-quarter profit, reversing a lost at the start of 2012, when the drug developer absorbed a sizeable pre-tax charge tied to a settlement and license agreement.

The Malvern, Pa., company said Tuesday it earned $15.3 million, or 14 cents per share, in the three months that ended March 31. That compared with a loss of $87.3 million, or 75 cents per share, in last year’s quarter. Adjusted earnings totaled $1.09 per share in the most recent quarter.

Revenue climbed nearly 3 percent to $708.5 million.

Analysts surveyed by FactSet expected, on average, adjusted earnings of $1.07 per share on $738.6 million in revenue.

In last year’s quarter, Endo absorbed a $110-million pre-tax charge tied to an agreement with Impax Laboratories Inc. Endo made the Impax payment as part of the settlement of a patent dispute over generic versions of Endo’s pain drug Opana ER.

In this year’s quarter, revenue climbed despite an 11 percent drop in sales of the company’s Lidoderm pain patch to $187 million. Revenue from Opana ER fell 31 percent to $56.3 million, as the drug faced generic competition and had a supply disruption at the end of last year’s quarter that caused some patients to switch to other products.

The company also recorded $36.1 million in sales from its joint pain treatment Voltaren Gel in this year’s quarter, after recording none last year due to manufacturing problems at a Lincoln, Neb., factory.

Endo reaffirmed its forecast for 2013 adjusted earnings of between $4.40 and $4.70 per share on between $2.8 billion and $2.95 billion in revenue.

Analysts expect, on average, earnings of $4.49 per share on $2.91 billion in revenue.

Company shares closed at $37.92 on Monday and have ranged between $25 and $38.05 over the past year.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE